Xilio Therapeutics Inc
XLO0.541USD
+0.021+4.04%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
28.03MMarket Cap
LossP/E TTM
More Details of Xilio Therapeutics Inc Company
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Xilio Therapeutics Inc Info
Ticker SymbolXLO
Company nameXilio Therapeutics Inc
IPO dateOct 22, 2021
CEORusso (Rene)
Number of employees64
Security typeOrdinary Share
Fiscal year-endOct 22
Address828 Winter Street
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone16174304680
Websitehttps://xiliotx.com/
Ticker SymbolXLO
IPO dateOct 22, 2021
CEORusso (Rene)
Company Executives of Xilio Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Director
Independent Director
70.00K
--
Dr. Rene Russo, Pharm.D.
Dr. Rene Russo, Pharm.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher (Chris) Frankenfield
Mr. Christopher (Chris) Frankenfield
Chief Financial Officer and Operating Officer
Chief Financial Officer and Operating Officer
--
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Robert W. (Rob) Ross, M.D.
Dr. Robert W. (Rob) Ross, M.D.
Independent Director
Independent Director
--
--
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Independent Director
Independent Director
--
--
Dr. Daniel J. Curran, M.D.
Dr. Daniel J. Curran, M.D.
Independent Director
Independent Director
--
--
Ms. Christina Rossi
Ms. Christina Rossi
Independent Director
Independent Director
--
--
Mr. Kevin Brennan
Mr. Kevin Brennan
Senior Vice President - Finance & Accounting
Senior Vice President - Finance & Accounting
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Director
Independent Director
70.00K
--
Dr. Rene Russo, Pharm.D.
Dr. Rene Russo, Pharm.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher (Chris) Frankenfield
Mr. Christopher (Chris) Frankenfield
Chief Financial Officer and Operating Officer
Chief Financial Officer and Operating Officer
--
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Robert W. (Rob) Ross, M.D.
Dr. Robert W. (Rob) Ross, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
19.07M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Dec 15
Updated: Mon, Dec 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
13.48%
GKCC, LLC
10.36%
Bain Capital Life Sciences Investors, LLC
6.76%
AbbVie, Inc.
6.44%
Coastlands Capital LP
6.41%
Other
56.54%
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
13.48%
GKCC, LLC
10.36%
Bain Capital Life Sciences Investors, LLC
6.76%
AbbVie, Inc.
6.44%
Coastlands Capital LP
6.41%
Other
56.54%
Shareholder Types
Shareholders
Proportion
Corporation
34.66%
Investment Advisor
11.48%
Hedge Fund
7.45%
Venture Capital
3.24%
Investment Advisor/Hedge Fund
1.32%
Individual Investor
0.68%
Research Firm
0.01%
Other
41.16%
Institutional Shareholding
Updated: Wed, Jan 21
Updated: Wed, Jan 21
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
48
14.32M
28.99%
--
2025Q4
65
15.72M
23.28%
-2.62M
2025Q3
65
13.13M
25.34%
-6.35M
2025Q2
74
35.70M
68.94%
+3.82M
2025Q1
76
35.65M
68.85%
+3.77M
2024Q4
70
35.35M
73.19%
+8.60M
2024Q3
67
30.96M
73.92%
+4.31M
2024Q2
73
31.95M
83.81%
+2.44M
2024Q1
95
22.55M
67.42%
+68.86K
2023Q4
95
18.91M
68.67%
-3.93M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilead Sciences Inc
9.11M
13.48%
--
--
Sep 30, 2025
GKCC, LLC
7.00M
10.36%
--
--
Oct 01, 2025
Bain Capital Life Sciences Investors, LLC
4.57M
6.76%
--
--
Sep 30, 2025
AbbVie, Inc.
4.35M
6.44%
+4.35M
--
Feb 11, 2025
Coastlands Capital LP
4.33M
6.41%
+4.33M
--
Dec 04, 2025
Merck & Co Inc
1.48M
2.2%
--
--
Sep 30, 2025
Takeda Pharmaceutical Co Ltd
1.48M
2.18%
--
--
Sep 30, 2025
RiverVest Venture Partners, LLC
1.44M
2.13%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
1.26M
1.86%
+104.67K
+9.09%
Sep 30, 2025
Morgan Stanley Smith Barney LLC
961.92K
1.42%
-482.41K
-33.40%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
